4.8 Article

Conditionally pathogenic genetic variants of a hematopoietic disease-suppressing enhancer

期刊

SCIENCE ADVANCES
卷 7, 期 50, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abk3521

关键词

-

资金

  1. NIH [DK68634]
  2. EvansMDS Foundation
  3. ASH Scholar Award
  4. Leukemia & Lymphoma Society Career Development Program
  5. NHLBI [T32 HL07899]
  6. Carbone Cancer Center [P30CA014520]
  7. NIH shared instrumentation grant [1S10RR025483-01]

向作者/读者索取更多资源

The study explores conditionally pathogenic enhancer motif variants that differentially affect hematopoietic development and regeneration, as well as an Ets motif variant that autonomously disrupts hematopoiesis in hematopoietic cells.
Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe conditionally pathogenic (CP) enhancer motif variants that differentially affect hematopoietic development and regeneration. The Ets motif variant functioned autonomously in hematopoietic cells to disrupt hematopoiesis. Because an epigenetically silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据